These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 25297785)
1. [Regulatory T cells in cancer immunotherapy]. Nishikawa H Rinsho Ketsueki; 2014 Oct; 55(10):2183-9. PubMed ID: 25297785 [No Abstract] [Full Text] [Related]
2. Introduction: Antibody-targeted therapy special issue. Kishimoto T Int Immunol; 2015 Jan; 27(1):1-2. PubMed ID: 25550277 [No Abstract] [Full Text] [Related]
3. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy. Brunner-Weinzierl MC; Rudd CE Front Immunol; 2018; 9():2737. PubMed ID: 30542345 [TBL] [Abstract][Full Text] [Related]
4. Coinhibitory Pathways in Immunotherapy for Cancer. Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206 [TBL] [Abstract][Full Text] [Related]
5. Targeting T Cell Co-receptors for Cancer Therapy. Callahan MK; Postow MA; Wolchok JD Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570 [TBL] [Abstract][Full Text] [Related]
7. Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg? Kremer L; Garcia-Sanz JA Front Immunol; 2018; 9():442. PubMed ID: 29556241 [No Abstract] [Full Text] [Related]
8. [Era of cancer immunotherapy has come]. Nakatsura T Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):164-71. PubMed ID: 27320931 [TBL] [Abstract][Full Text] [Related]
10. Introduction: Cancer Immunology Special Issue-Immunotherapy. Kawakami Y Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100 [No Abstract] [Full Text] [Related]
11. New checkpoints in cancer immunotherapy. Ni L; Dong C Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699 [TBL] [Abstract][Full Text] [Related]
12. Therapy implications of the role of interleukin-2 in cancer. Lissoni P Expert Rev Clin Immunol; 2017 May; 13(5):491-498. PubMed ID: 27782752 [TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells: a potential target in cancer immunotherapy. Shitara K; Nishikawa H Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262 [TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy comes of age and looks for maturity. Finck A; Gill SI; June CH Nat Commun; 2020 Jul; 11(1):3325. PubMed ID: 32620755 [TBL] [Abstract][Full Text] [Related]
15. [Immuno-oncology--silver bullets or mass destruction weapons?]. Utriainen M; Rämet M Duodecim; 2016; 132(8):721-8. PubMed ID: 27244931 [TBL] [Abstract][Full Text] [Related]
16. Part II: Checkpoint inhibitors in cancer therapy. Daud AI Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974 [No Abstract] [Full Text] [Related]
17. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Furness AJ; Quezada SA; Peggs KS Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975 [No Abstract] [Full Text] [Related]
18. Update on the current revolution in cancer immunotherapy. Renrick AN; Dunbar ZT; Shanker A Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010 [No Abstract] [Full Text] [Related]
19. New checkpoint inhibitors ride the immunotherapy tsunami. Mullard A Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256 [No Abstract] [Full Text] [Related]
20. Immune agonist antibodies face critical test. Garber K Nat Rev Drug Discov; 2020 Jan; 19(1):3-5. PubMed ID: 31907434 [No Abstract] [Full Text] [Related] [Next] [New Search]